Product Pipeline Summary
-
Anti-Chemokine and Anti-Chemokine Receptor Antibodies
JYANT's patented approach provides a means of inhibiting the growth and metastasis of cancer cells by administering high affinity anti-chemokine antibodies. JYANT's proprietary technology also allows for the early detection of cancers that secrete and/or expression chemokine and chemokine receptors. Among the chemokine and chemokine receptors targeted by these methods include CXCL13, CXCL16, CCL25, CXCR5, CXCR6, and CCR9.
JYANT has developed and was first to patent the use of anti-chemokine and anti-chemokine receptor antibodies to inhibit inflammatory processes. JYANT's proprietary approach enables the detection and progression of inflammatory diseases that cause elevated expression of chemokine and chemokine receptors. The chemokine and chemokine receptors targeted by JYANT's antibodies include CXCL9, CXCL10, CXCL11, CXCL13, CXCR3, and CXCR5.
-
Chemokine Receptor Protein Antagonists
JYANT also utilizes unique chemokine-immunoglobulin and -polyethylene glycol (PEG) fusion polypeptide compositions to treat cancers and inflammatory disorders. This patented technology permits chemokine receptor blockade with high affinity (< 100 pM) protein antagonists having one-week serum half-lives.
-
XPclad - Nanocompounding
JYANT's patented nanotechnology applications provide novel methods for the preparation and modification of biodegradable and biocompatible nano- and micro-particles. This novel and inexpensive technique enables particle generation and encapsulation of biologicals and pharmaceuticals with precise excipient/biopolymer concentrations, curing conditions, and planetary ball milling to produce either nano- and micro-particles of a controllable size without altering the encapsulated contents. The resulting particles can deliver soluble or insoluble biologicals, heavy metals, diagnostic agents and/or therapeutics across mucosal surfaces or solubilize previously insoluble molecules for parenteral administration.
Therapeutic Product Pipeline At-A-Glance
| Product (Target) | Indication | Pre-Clin. | Phase 1 | Phase 2 | Phase 3 |
| JT02 (CXCL10) | IBD | ||||
| JT03 (CXCL13) | RA, Solid Tumors | ||||
| JT04 (CCL25) | Solid Tumors | ||||
| JT05 (CXCL16) | Solid Tumors | ||||
| JT06 (CXCL11) | MS | ||||
| JT07 (CXCR3 CXCR7) | IBD, Solid Tumors | ||||
| JT08 (CXCR5) | Solid Tumors | ||||
| Nanocisplatin | Solid Tumors | ||||
| Nanoflavopiridol | HRPC | ||||
| Nanocurcumin | RA, Solid Tumors | ||||
| Nanoresveratrol | Solid Tumors |
Diagnostic Product Pipeline (coming soon)